Novel approaches to anticonvulsant drug discovery

Expert Opinion on Drug Discovery

Volumn 8, Issue 11, 2013, Pages 1415-1427

  Miziak, Barbara ^a   Chrościńska Krawczyk, Magdalena ^a   Błaszczyk, Barbara ^b   Radzik, Iwona ^a   Czuczwar, Stanisław J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Faculty of Health Sciences   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Antiepileptogenic drugs; Drug resistance; Epilepsy; Seizures

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ANTICONVULSIVE AGENT; BRIVARACETAM; CAFFEINE; CALCIUM CHANNEL; CARBAMAZEPINE; DIAZEPAM; ESLICARBAZEPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; GANAXOLONE; GLUTAMIC ACID; ISOVALERAMIDE; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RETIGABINE; STIRIPENTOL; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN;

ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; BEVERAGE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; KINDLING; LIVER FAILURE; LIVER TOXICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOKING; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HISTORY, 15TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; NERVE DEGENERATION;

EID: 84886633604     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.837047     Document Type: Review

References (106)

1. Gross RA. A brief history of epilepsy and its therapy in the Western Hemisphere. Epilepsy Res 1992;12: 65-74
2. Magiorkinis E, Sidiropoulou K, Diamantis A. Hallmarks in the history of epilepsy: epilepsy in antiquity. Epilepsy Behav 2010;17: 103-8
3. Foyaca-Sibat H. Novel aspects on epilepsy. InTech; Rijeka: Croatia: 2011
4. Longrigg J. Epilepsy in ancient Greek medicine-the vital step. Seizure 2000;9: 12-21
5. Fatović-Ferencić S, Dürrigl MA. The sacred disease and its patron saint. Epilepsy Behav 2001;2: 370-3
6. Reynolds EH, Rodin E. The clinical concept of epilepsy. Epilepsia 2009;50(Suppl 3): 2-7
7. Bladin PF, Eadie MJ. A disease once sacred: a history of the medical understanding of epilepsy. JohnLibbey; Eastleigh: England: 2001
8. Eadie MJ. Sir Charles Locock and potassium bromide. J R Coll Physicians Edinb 2012;42: 274-9
9. Wieser HG. Treatment of epilepsy: where are we today?. [Article in German]. Praxis (Bern 1994) 1996;85: 74-9
10. Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia 2012;53(Suppl 8): 26-39
11. Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010;19: 650-5
12. Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937;85: 525-6
13. Glazko AJ. Discovery of phenytoin. Ther Drug Monit 1986;8: 490-7
14. Young RS, Alger PM, Bauer L, Lauderbaugh D. A randomized, double-blind, crossover study of phenobarbital and mephobarbital. J Child Neurol 1986;1: 361-3
15. Aiken SP, Brown WM. Treatment of epilepsy: existing therapies and future developments. Front Biosci 2000;5:E124-52
16. Gallagher BB, Baumel IP, Woodbury SG, Dimicco JA. Clinical evaluation of eterobarb, a new anticonvulsant drug. Neurology 1975;25: 399-404
17. Bogue JY, Carrington HC. The evaluation of "mysoline", a new anticonvulsant drug. Br J Pharmacol Chemother 1953;8: 230-6
18. Bialer M. How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 2012;53(Suppl(8): 3-11
19. Heathfield KW, Jewesbury EC. Treatment of petit mal with ethosuximide. Br Med J 1961;2: 565-7
20. Schindler W. 5H-Dibenz[b,f]azepines. US2948718; 1960
21. Schatzberg A, Nemeroff CB. Textbook of psychopharmacology. American Psychiatric Press; Washington DC: 1995
22. Meunier H, Carraz G, Neunier Y, et al. Pharmacodynamic properties of N-dipropylacetic acid. [Article in French]. Therapie 1963;18: 435-8
23. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003;37(Suppl 2): 5-16
24. Carraz G, Darbon Lebreton S, Beriel H. Pharmacodynamic properties of 2,2-dipropylacetic acid and its derivatives. 4th report: 2,2 dipropylacetamide. [Article in French]. Therapie 1964;19: 468-76
25. Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19: 315-59
26. Lason W, Dudra-Jastrzebska M, Rejdak K, Czuczwar SJ. Basic mechanism of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 2011;63: 271-92
27. Keck PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002;63(Suppl(4): 3-11
28. Smith M, Wilcox KS, White HS. Discovery of antiepileptic drugs. Neurotherapeutics 2007;4: 12-17
29. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5: 3-14
30. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27: 27-34
31. Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994;17: 389-402
32. Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-Daspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000;39: 47-55
33. De Sarro G, Ongini E, Bertorelli R, et al. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol 1994;262: 11-19
34. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 1994;35: 229-34
35. Morris GL. Gabapentin. Epilepsia 1999;40(Suppl 5):S63-70
36. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(Suppl 6):S4-11
37. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34: 1-41
38. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271: 5768-76
39. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl(1):S2-9
40. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997;38: 959-65
41. Macdonald RL, Greenfield LJ Jr. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997;10: 121-8
42. Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998;34: 335-4
43. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51: 31-71
44. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55: 437-60
45. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41: 1364-74
46. Meldrum BS. Gamma-aminobutyric acid and the search for new anticonvulsant drugs. Lancet 1978;2: 304-6
47. Schechter PJ, Tranier Y, Jung MJ, Böhlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45: 319-28
48. Kleinrok Z, Czuczwar SJ, Kozicka M. Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 1980;21: 519-29
49. Czuczwar SJ. Effect of combined treatment with dopaminergic and GABA-ergic drugs on the threshold for maximal electroconvulsions in mice. Pol J Pharmacol Pharm 1981;33: 25-35
50. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15: 339-50
51. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011;20: 359-68 .. A very interesting review paper on the currently used seizure models and their disadvantages with some proposals for new strategies in the search for new AEDs.
52. Beyenburg S, Bauer J, Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 2004;80: 581-7
53. Stȩpień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012;64: 1011-19
54. Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52: 657-78
55. Brandt C, Gastens AM, Sun MZ, et al. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006;51: 789-804. The results clearly show that chronic administration of valproate does not prevent epileptogenesis.
56. Bolanos AR, Sarkisian M, Yang Y, et al. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 1998;51: 41-8. A partial inhibitory effect of valproate on spontaneous seizures in rats was shown. However, phenobarbital and topiramate were ineffective in this regard.
57. Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Neuroprotective properties of topiramate in the lithium - pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004;308: 787-95. Lack of topiramate's effect on spontaneous seizures in rats.
58. Pitkanen A, Kharatishvili I, Narkilahti S, et al. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res 2005;63: 27-42. A very potent action of diazepam given as a single dose for preventing the occurrence of spontaneous seizure activity.
59. Chroscinska-Krawczyk M, Jargiello-Baszak M, Walek M, et al. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol Rep 2011;63: 12-18
60. Czuczwar SJ, Gasior M, Janusz W, et al. Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice. Epilepsia 1990;31: 318-23
61. Czuczwar SJ, Kleinrok Z. Modulation of the protective efficacy of common antiepileptic drugs by xanthine derivatives: implications for the clinical use of xanthines in epileptic patients. Pharmacol Res 1990;22: 661-5
62. Dworetzky BA, Bromfield EB, Townsend MK, Kang JH. A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II. Epilepsia 2010;51: 198-205
63. Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. Seizure 2003;12: 519-21
64. Bonilha L, Li LM. Heavy coffee drinking and epilepsy. Seizure 2004;13: 284-5
65. Gilbert RM, Marshman JA, Schwieder M, Berg R. Caffeine content of beverages as consumed. Can Med Assoc J 1976;114: 205-8
66. Smith JM, Pearson S, Marks V. Plasma caffeine concentration in outpatients. Lancet 1982;2: 985-6
67. Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, et al. Coffee consumption and health-related quality of life. Clin Nutr 2013;published online 13 April 2013; doi: 10.1016/j.clnu.2013.04.004
68. Czuczwar M, Kis J, Czuczwar P, et al. Nicotine diminishes anticonvulsant activity of antiepileptic drugs in mice. Pol J Pharmacol 2003;55: 799-802
69. Sood N, Sahai AK, Medhi B, Chakrabarti A. Dose-finding study with nicotine as a proconvulsant agent in PTZ-induced seizure model in mice. J Biomed Sci 2008;15: 755-65
70. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 314-19
71. Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, et al. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin Drug Metab Toxicol 2009;5: 131-6
72. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002;11: 349-51
73. Merritt HH, Putnam TJ. Landmark article Sept 17, 1938: sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam. JAMA 1984;251: 1062-7
74. Friedlander WJ. Putnam, Merritt, and the discovery of Dilantin. Epilepsia 1986;27(Suppl(3):S1-20
75. Borowicz KK, Piskorska B, Kimber-Trojnar Z, et al. Is there any future for felbamate treatment? Pol J Pharmacol 2004;56: 289-94
76. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61: 197-216
77. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5: 627-35
78. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006;15: 637-47
79. Freidel M, Krause E, Kuhn K, et al. Oxcarbazepine in the treatment of epilepsy. [Article in German]. Fortschr Neurol Psychiatr 2007;75: 100-6
80. Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, et al. New generation of valproic acid. Pol J Pharmacol 2004;56: 283-8
81. Botros S, Khalil NA, Naguib BH, El-Dash Y. Synthesis and anticonvulsant activity of new phenytoin derivatives. Eur J Med Chem 2013;60: 57-63
82. Drabczynska A, Yuzienko O, Köse M, et al. Synthesis and biological activity of tricyclic cycloalkilimidazo-, pyrimidoand diazepinopurinediones. Eur J Med Chem 2011;46: 3590-607
83. Szkaradek N, Gunia A, Waszkielewicz AM, et al. Anticonvulsant evaluation of aminoalkanol derivatives of 2- and 4-methylxanthone. Bioorg Med Chem 2013;21: 1190-8
84. Amir M, Ali I, Hassan MZ. Design and synthesis of some new quinazolin-4- (3H)-ones as anticonvulsant and antidepressant agents. Arch Pharm Res 2013;36: 61-8
85. Plech T, Luszczki JJ, Wujec M, et al. Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles. Eur J Med Chem 2013;60: 208-15
86. Luszczki JJ, Kominek M, Florek-Luszczki M, et al. Influence of N-hydroxymethyl-pisopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Epilepsy Res 2012;100: 27-36
87. Löscher W. New visons in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342: 1-13
88. Urbanska E, Czuczwar SJ, Kleinrok Z, Turski WA. Excitatory amino acids in epilepsy. Restor Neurol Neurosci 1998;13: 25-39
89. Czuczwar SJ, Swiader M, Kuzniar H, et al. LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol 1998;359: 103-9
90. Zaccara G, Giovanelli F, Cincotta M, Iudice A. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. Expert Rev Neurother 2013;13: 647-55
91. Simonato M, Löscher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012;53: 1860-7
92. Acharya MM, Hattiangady B, Shetty AK. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008;84: 363-404 .. This review focuses on the search for novel antiepileptogenic agents.
93. Hartman AL, Lyle M, Rogawski MA, Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008;49: 334-9
94. Thavendiranathan P, Chow C, Cunnane S, Burnham WM. The effect of the 'classic' ketogenic diet on animal seizure models. Brain Res 2003;959: 206-13
95. Cross JH, Mclellan A, Neal EG, et al. The ketogenic diet in childhood epilepsy: where are we now? Arch Dis Child 2010;95: 550-3
96. Dhamija R, Eckert S, Wirrell E. Ketogenic diet. Can J Neurol Sci 2013;40: 158-67
97. Todorova MT, Tandon P, Madore RA, et al. The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy. Epilepsia 2000;41: 933-40
98. Hansen SL, Nielsen AH, Knudsen KE, et al. Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus. Meurochem Int 2009;54: 199-204
99. Linard B, Ferrnandon A, Koning E, et al. Ketogenic diet exhibits neuroprotective effects in hippocampus but fails to prevent epileptogenesis in the lithium-pilocarpine model of mesial temporal lobe epilepsy in adult rats. Epilepsia 2010;51: 1829-36
100. Czuczwar SJ, Turski L, Turski W, Kleinrok Z. Effects of some antiepileptic drugs in pentetrazol-induced convulsions in mice lesioned with kainic acid. Epilepsia 1981;22: 407-14
101. Czuczwar SJ, Turski L, Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia 1982;23: 377-82
102. Margineanu DG. Systems biology impact on antiepileptic drug discovery. Epilepsy Res 2012;98: 104-15
103. Wu Z, Xu Q, Zhang L, et al. Protective effect of reservatrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res 2009;34: 1393-400
104. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011;10: 173-86 .. The authors review differential strategies for the prevention of experimental head trauma-induced epileptogenesis.
105. Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 2013;10: 30
106. Immonen R, Kharatishvili I, Gröhn O, Pitkanen A. MRI biomarkers for post-traumatic epileptogenesis. J Neurotrauma 2013;30: 1305-9